CoChat
Sign Up
Cited by 159Schizophrenia research and treatmentPsychological Testing and AssessmentDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia

Green, Michael F., Schooler, Nina R., Kern, Robert S., Frese, Fred J., Granberry, Wendy, Harvey, Philip D., Karson, Craig N., Peters, Nancy, Stewart, Michelle, Seidman, Larry J., Sonnenberg, John, Stone, William S., Walling, David, Stover, Ellen, Marder, Stephen R.·2011·American Journal of Psychiatry
DOI 10.1176/appi.ajp.2010.10030414
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Because reduction of psychotic symptoms in schizophrenia does not result in adequate community functioning, efforts have shifted to other areas, such as cognitive impairment. The U.S. Food and Drug Administration requires that drugs for cognition enhancement in schizophrenia show improvement on two distinct outcome measures in clinical trials: an accepted cognitive performance battery and a functionally meaningful coprimary measure. The authors examined the reliability, validity, and practicality of functionally meaningful measures. METHOD: In this four-site validation study, schizophrenia patients were assessed at baseline (N=166) and 4 weeks later (N=144) on performance-based (Independent Living Scales, Test of Adaptive Behavior in Schizophrenia [TABS], and UCSD Performance-based Skills Assessment [UPSA]) and interview-based (Cognitive Assessment Interview and Clinical Global Impression Scale for Cognition) candidate coprimary measures. In addition, cognitive performance, community functioning, and clinical symptoms were assessed. Both full and short forms of the performance-based measures were evaluated. RESULTS: All measures were well tolerated by patients, had adequate test-retest reliability, and showed good utility as a repeated measure. Measures differed in their correlation with cognitive performance, with performance-based measures having stronger correlations than interview-based measures. None of the measures had notable floor or ceiling effects or missing data. CONCLUSIONS: Among the full-form measures, the UPSA was judged to have the strongest overall properties. Among the short forms, the TABS and UPSA appeared to have the strongest features. Use of the short forms saves time, but at the cost of lower test-retest reliability and weaker correlations with cognitive performance.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2010.10030414

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 5

  1. Nuechterlein KH, 2006, MATRICS Consensus Cognitive Battery
  2. 10.1037/0021-843X.103.2.371 · DOI
  3. Loeb PA, 1996, Independent Living Scales Manual
  4. Reise SP, Psychol Assess
  5. Kern RS, Schizophr Res

Cited by

Sorted by citations

See all 159

Related

See all

Metadata

Authors
Green, M. F., Schooler, N. R., Kern, R. S., Frese, F. J., Granberry, W., Harvey, P. D., Karson, C. N., Peters, N., Stewart, M., Seidman, L. J., Sonnenberg, J., Stone, W. S., Walling, D., Stover, E., & Marder, S. R.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Green, Michael F.
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2011-04
Volume
168
Issue
4
Pages
400-407
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.2010.10030414
OpenAlex
W2151080668
Cited by
159
References
23
Citations by year
2026: 3 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 11 · 2021: 3 · 2020: 7 · 2019: 8 · 2018: 13 · 2017: 6 · 2016: 12 · 2015: 18 · 2014: 12 · 2013: 18 · 2012: 23
FWCI
14.20
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Public Health Service (HHSN278 200441003C)
  • National Institute of Mental Health (MH042392)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
schizophrenia, cognitive enhancement, community functioning, test-retest reliability, performance-based measures, cognitive impairment
MeSH terms
Activities of Daily Living, Adult, Clinical Trials as Topic, Cognition, Female, Humans, Interviews as Topic, Male, Neuropsychological Tests, Psychometrics, Quality of Life, Schizophrenia, Schizophrenic Psychology, Reproducibility of Results, Outcome Assessment, Health Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review